elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board
elbion AG announced that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company.
Taapken (40), previously spent 3 years as a Partner in the life science team of DVC, Deutsche Venture Capital, and was a member of the supervisory board of elbion AG. He has resigned from DVC, and has also stepped down from his position as a supervisory board member of the company, to join elbion's management board. Prior to his position at DVC, Thomas Taapken worked for 8 years at Sanofi-Aventis in the areas of research, corporate development and venture capital. In his last position he held responsibility for the corporate venture capital activities of the group. Dr. Taapken holds a PhD in chemistry from the Technical University of Berlin.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.